| REVIEW ARTICLE |
|
| Year : 2005 | Volume
: 11
| Issue : 1 | Page : 1-19 |
|
|
Diagnosis and treatment of viral liver fibrosis
Thierry Poynard, Francoise Imbert-Bismut, Mona Munteanu, Vlad Ratziu
Groupe Hospitalier Pitie-Salpetriere, Paris, France
Correspondence Address:
Thierry Poynard
Groupe Hospitalier Pitie-Salpetriere, 47-83 Boulevard de I'Hospital, 75651 Paris Codex 13
France
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1319-3767.33332
|
|
|
This review summarized the diagnostic value of fibrosis biomarkers and the efficacy of anti-viral treatments on fibrosis progression. Noninvasive biomarkers can facilitate the screening and management of chronic hepatitis C and B. Screening for significant fibrosis is-mandatory as very effective anti-viral treatments are available, permitting to stop or to reduce the fibrosis progression. The reduction of fibrosis progression will decrease the mortality due to complications of cirrhosis. In patients with chronic hepatitis C, pegylated interferons combined with ribavirin are effective in reducing fibrosis progression. In patients with chronic hepatitis B, lamivudine, adefovir and pegylated interferon are also effective in reducing fibrosis progression. In patients with chronic hepatitis Delta, pegylated interferon is also effective in reducing fibrosis progression |
|
|
|
| [FULL TEXT] [PDF Not available]* |
|
 |
|
